ANDRAS HECZEY to Neuroblastoma
This is a "connection" page, showing publications ANDRAS HECZEY has written about Neuroblastoma.
Connection Strength
3.724
-
GD2-CAR CAR T?cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter. Cancer Cell. 2024 01 08; 42(1):8-10.
Score: 0.625
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
Score: 0.600
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
Score: 0.501
-
50 Years Ago in The Journal of Pediatrics: Survival of Children with Neuroblastoma Treated with Combination Chemotherapy. J Pediatr. 2018 12; 203:233.
Score: 0.440
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.398
-
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
Score: 0.325
-
Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013 Dec; 16(90):287-94.
Score: 0.311
-
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
Score: 0.124
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
Score: 0.116
-
Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2017 11; 39(8):e486-e488.
Score: 0.102
-
IMAGES IN CLINICAL MEDICINE. Osteopetrosis and Erlenmeyer-Flask Deformity. N Engl J Med. 2015 Sep 03; 373(10):e12.
Score: 0.088
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
Score: 0.070
-
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
Score: 0.023